DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

Genetic testing is recommended for those with personal and family histories of several types of cancer — including pancreatic ...

The new NCCN Guidelines for Patients®: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer is ...

Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug development landscape for ...

A new resource from the National Comprehensive Cancer Network (NCCN) provides evidence-based guidance on assessing and ...

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced ...

A new analysis of the Breast Cancer Index (BCI) may help identify women with HR-positive breast cancer who could potentially ...

For women with newly diagnosed invasive breast cancer (BC), weight gain is associated with an increased risk for heart ...